CO6720990A2 - Una nueva variante del factor viii antihemofílico con actividad específica aumentada - Google Patents

Una nueva variante del factor viii antihemofílico con actividad específica aumentada

Info

Publication number
CO6720990A2
CO6720990A2 CO13136450A CO13136450A CO6720990A2 CO 6720990 A2 CO6720990 A2 CO 6720990A2 CO 13136450 A CO13136450 A CO 13136450A CO 13136450 A CO13136450 A CO 13136450A CO 6720990 A2 CO6720990 A2 CO 6720990A2
Authority
CO
Colombia
Prior art keywords
factor viii
specific activity
increased specific
new variant
antihemophilic factor
Prior art date
Application number
CO13136450A
Other languages
English (en)
Spanish (es)
Inventor
Chee Kong Lai
Roddy Kevin Stafford
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of CO6720990A2 publication Critical patent/CO6720990A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CO13136450A 2010-11-05 2013-06-05 Una nueva variante del factor viii antihemofílico con actividad específica aumentada CO6720990A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05

Publications (1)

Publication Number Publication Date
CO6720990A2 true CO6720990A2 (es) 2013-07-31

Family

ID=46025129

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13136450A CO6720990A2 (es) 2010-11-05 2013-06-05 Una nueva variante del factor viii antihemofílico con actividad específica aumentada

Country Status (18)

Country Link
US (2) US9150637B2 (enExample)
EP (1) EP2635297B1 (enExample)
JP (1) JP5922141B2 (enExample)
KR (1) KR101948337B1 (enExample)
CN (1) CN103298483B (enExample)
AU (1) AU2011323236B2 (enExample)
BR (1) BR112013011041B1 (enExample)
CA (1) CA2816575C (enExample)
CO (1) CO6720990A2 (enExample)
DK (1) DK2635297T3 (enExample)
EA (1) EA035447B1 (enExample)
ES (1) ES2721478T3 (enExample)
IL (1) IL226158B (enExample)
MX (2) MX347503B (enExample)
MY (1) MY165089A (enExample)
SG (2) SG190136A1 (enExample)
WO (1) WO2012061689A2 (enExample)
ZA (1) ZA201303816B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250226B1 (en) 2015-01-30 2020-07-15 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
JP7235511B2 (ja) 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖fviiiおよびその化学コンジュゲート

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
EP0710288B1 (en) 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α1プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
WO1997040145A1 (en) * 1996-04-24 1997-10-30 The Regents Of The University Of Michigan Inactivation resistant factor viii
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1036177A1 (en) 1997-12-05 2000-09-20 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
DE60024268T2 (de) 1999-07-13 2006-08-03 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7576182B1 (en) 1999-08-31 2009-08-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
ES2319745T3 (es) 2001-10-05 2009-05-12 Expression Therapeutics, Llc Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso.
US20040249134A1 (en) 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
DK1750733T3 (da) 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
US20090271163A1 (en) * 2007-12-06 2009-10-29 Wyeth Crystal structure of human factor VIII and uses thereof

Also Published As

Publication number Publication date
SG190136A1 (en) 2013-07-31
CA2816575A1 (en) 2012-05-10
JP2013545459A (ja) 2013-12-26
MX2013005047A (es) 2013-12-06
EP2635297A4 (en) 2014-06-25
JP5922141B2 (ja) 2016-05-24
ES2721478T3 (es) 2019-07-31
US20150353625A1 (en) 2015-12-10
KR20140114266A (ko) 2014-09-26
IL226158B (en) 2019-08-29
AU2011323236A8 (en) 2013-07-25
MY165089A (en) 2018-02-28
SG10201509149VA (en) 2015-12-30
WO2012061689A3 (en) 2012-10-04
US20130296244A1 (en) 2013-11-07
AU2011323236A1 (en) 2013-06-06
US9150637B2 (en) 2015-10-06
MX347503B (es) 2017-04-26
BR112013011041B1 (pt) 2021-05-25
EA201390654A1 (ru) 2014-01-30
US10053500B2 (en) 2018-08-21
WO2012061689A2 (en) 2012-05-10
MX351220B (es) 2017-10-05
IL226158A0 (en) 2013-06-27
EP2635297B1 (en) 2019-02-27
AU2011323236B2 (en) 2017-03-30
CN103298483B (zh) 2017-04-12
EA035447B1 (ru) 2020-06-17
ZA201303816B (en) 2021-05-26
EP2635297A2 (en) 2013-09-11
CN103298483A (zh) 2013-09-11
DK2635297T3 (da) 2019-05-06
CA2816575C (en) 2019-06-11
KR101948337B1 (ko) 2019-02-14
BR112013011041A2 (pt) 2017-06-06

Similar Documents

Publication Publication Date Title
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20110138A (es) Artículos con una serie de objetos gráficos que proporcionan una señal funcional
BR112013028512A2 (pt) cápsula
BR112014001219A2 (pt) perfume
UY34961A (es) Nanocarbono que contiene caucho natural
BR112013025580A2 (pt) barra de sabão transparente e processo par a fabricação das barras de sabão transparentes
CR20120494S (es) Empaque blister para producto
BR112013026462A2 (pt) protetor de pé
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
BR112013024562A2 (pt) fios de fibra de vidro e produtos reforçados compreendendo os mesmos
MX2015007712A (es) Polipeptidos del factor vii de accion corta.
UY34140A (es) Mejoras en el riego
GT201300015S (es) Una lampara de combinacion delantera para motoneta
BR112013025764A2 (pt) dispositivo impulsionador
CO6720990A2 (es) Una nueva variante del factor viii antihemofílico con actividad específica aumentada
NI201300144A (es) Composición farmacéutica en forma de una suspensión oral que comprende una fracción flavonoica y goma de xantano.
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
UY4162Q (es) Configuración aplicada a zapato
AU345056S (en) Bracket
CR20120191S (es) Linterna
RU2011100853A (ru) Астаксантин для стоматологических средств
AU340117S (en) Shelving
AU342487S (en) Inverter
RU2011106405A (ru) Мощная полупроводниковая структура